Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Bronchitis Clear all
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

NCT00970268
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Not listed Not applicable Interventional Results available

Gala Early Feasibility Study of RheOx

NCT03631472
View directory record Official record
Conditions
Chronic Bronchitis, Copd Bronchitis
Interventions
RheOx
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Not applicable Interventional

eRT Remote Health Monitoring

NCT01495780
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Chronic Obstructive Lung Disease, Bronchitis, Chronic, Pulmonary Emphysema
Interventions
Remote Health Monitoring
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Not applicable Interventional Results available

Procalcitonin Antibiotic Consensus Trial (ProACT)

NCT02130986
View directory record Official record
Conditions
Lower Respiratory Tract Infection (LRTI)
Interventions
Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician, Telephone Visit
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

NCT01049360
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg, Formoterol 12 μg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Glendale, Arizona • Pheonix, Arizona • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 1Phase 2 Interventional

Real-Time Support for Exercise Persistence in COPD

NCT00373932
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Emphysema, Chronic Bronchitis
Interventions
Coached exercise persistence intervention, Self-Monitored exercise persistence intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Not applicable Interventional Results available

The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD

NCT02099799
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis
Interventions
Pedometer and Website
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 2:01 PM EDT
Withdrawn Not applicable Interventional

Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects

NCT02341183
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
tPAD, 7% hypertonic saline (510K approved as a device)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 20, 2026, 2:01 PM EDT
Not listed Not applicable Interventional

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

NCT01599884
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
N-acetylcysteine, Oral acetylcysteine
Drug
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
40 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 4 Interventional Results available

Dose of Corticosteroids in COPD

NCT01742338
View directory record Official record
Conditions
COPD
Interventions
Low Dose Corticosteroids, High Dose Corticosteroids
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01437540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT00250679
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting No phase listed Observational

Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study

NCT01177618
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Not listed Phase 4 Interventional

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography

NCT01361984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
Interventions
Nebulized arformoterol, Salmeterol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Not applicable Interventional

A Study of Tobacco Smoke and Children With Respiratory Illnesses

NCT03062709
View directory record Official record
Conditions
Bronchiolitis, Pneumonia, Reactive Airway Disease, Asthma, Tobacco Smoking, Tobacco Cessation, Bronchopulmonary Dysplasia
Interventions
Breathe Easy Coalition written materials, Maine Tobacco Helpline, Urine cotinine testing
Behavioral · Diagnostic Test
Lead sponsor
MaineHealth
Other
Eligibility
Up to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

NCT00949975
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
AZD9668, AZD9668 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Fullerton, California • Valparaiso, Indiana • Council Bluffs, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01551888
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium/formoterol 400/12μg, Formoterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol tartrate inhalation solution, Salmeterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
65
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated No phase listed Observational

The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort

NCT02838108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 20, 2026, 2:01 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

NCT00608764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 80 Years
Enrollment
10,718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

NCT00648245
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 20, 2026, 2:01 PM EDT